Trials / Completed
CompletedNCT00136734
Methylphenidate Treatment for Cocaine Abuse and ADHD - 1
Methylphenidate Treatment for Cocaine Abuse and ADHD
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- New York State Psychiatric Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Many cocaine dependent individuals are also diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Methylphenidate (Ritalin) is currently approved to treat individuals diagnosed with ADHD. The purpose of this study is to determine the effectiveness of methylphenidate in treating ADHD symptoms in cocaine dependent individuals.
Detailed description
Methylphenidate (MPH) is commonly used to treat individuals diagnosed with ADHD. The purpose of this study is to determine the effectiveness of MPH in treating adult cocaine dependent individuals who are also diagnosed with ADHD. Participants in this 14-week, double-blind, placebo-controlled study will be randomly assigned to receive either sustained-release MPH or placebo. All participants will receive individual cognitive behavioral therapy. The trial will last 14 weeks. It will include a 1-week placebo lead-in phase and a 2-week dose titration phase, followed by 11 weeks on a stable dose of MPH. During the titration phase, MPH will be given twice a day, starting at a dose of 10 mg/day. The dose will increase by 10 mg each day, until a final stable dose of 40 mg/day is reached. At this time, sustained-release MPH will be given as two 20 mg doses (one in the morning and one in the afternoon). Depending on a participant's tolerance of MPH, the dose will be increased to a maximum of 60 mg/day (40 mg in the morning and 20 mg in the afternoon). Participants who are unable to tolerate a dose of at least 40 mg/day of MPH will be discontinued from the study. Assessments of ADHD symptoms will be completed at weekly study visits. In addition, drug use assessments will also be completed and will include self-reports and urine toxicology tests.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylphenidate | |
| OTHER | placebo | placebo |
Timeline
- Start date
- 1998-04-01
- Primary completion
- 2004-03-01
- Completion
- 2004-03-01
- First posted
- 2005-08-29
- Last updated
- 2019-04-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00136734. Inclusion in this directory is not an endorsement.